Attendee search 

Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK.

BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK.

BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.

- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.

The identified protein domains are  used to quickly develop binding/activity assays for use in small molecule hit screening and/or to provide protein for structural studies. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging drug discovery programs. Domainex's approach enhances drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.

Doaminex also has an internal pipeline of novel cancer therapeutics.  The lead program is available for licensing and is a kinase inhibitor against the targets TBK1/IKKe.  Earlier programs in Domainex's pipeline include a number of epigenetic targets, such as the lysine methyltransferase, G9a.

Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.  The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials.  This optimisation improves the efficacy of combinations in pre-clinical xenografts.

The company is also developing:

• Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.
• Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.
• Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.

Physiomics has worked with Eli Lilly since 2007 and recently added a further large pharmaceutical client. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel.  Fee-for-service, licensing and revenue sharing options are available.

Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.  The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.